Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
Texas Tech University Health Sciences Center
Summary
The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Age range: 18-65 years old 2. Scheduled or being scheduled to undergo robotic sleeve gastrectomy by Dr. Goyal. 3. Is able to provide written informed consent. 4. Is able to adhere to the study visit schedule and complete all study assessments. Exclusion Criteria: 1. Positive urine drug screen prior to surgery 2. History of substance abuse in the past year-by self report 3. Patient with ongoing daily narcotic use at the time of surgery-by self report 4. Inability to understand informed consent or read English/Spanish 5. Pregnant or lactating patients 6. Prisoners 7. Pa…
Interventions
- DrugZynrelef
Zynrelef will be injected at the 12mm port site
- DrugExparel
Exparel will be injected at the 12mm port site
Location
- Texas Tech University Health Sciences CenterLubbock, Texas